Tamoxifen v placebo at median follow up of 50 months‡
| Outcomes | Tamoxifen | Placebo | RRR (95% CI) | NNT (CI) |
|---|---|---|---|---|
| Breast cancer | 1.9% | 2.8% | 32% (8 to 50) | 111 (61 to 502) |
| RRI (CI) | NNH (CI) | |||
|---|---|---|---|---|
| ‡Abbreviations defined in glossary; RRR, RRI, NNT, NNH, and CI calculated from data in article. | ||||
| Endometrial cancer | 0.31% | 0.14% | 119% (−20 to 503) | Not significant |
| Thromboembolic events | 1.2% | 0.48% | 152% (45 to 338) | 138 (85 to 320) |
| Cardiovascular events | 2.0% | 1.8% | 15% (−17 to 61) | Not significant |
| All cause mortality | 0.70% | 0.31% | 127% (13 to 353) | 256 (133 to 1530) |